BTK Inhibitors: What Pharmacists Need To Know The PJ Pod podcast

Artwork

Science PJ Pod Pharmaceutical Journal

Indhold leveret af The PJ Pod and Pharmaceutical Journal. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The PJ Pod and Pharmaceutical Journal eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

The PJ Pod « »
BTK inhibitors: what pharmacists need to know

12M ago 31:54

Del

MP3•Episode hjem

Indhold leveret af The PJ Pod and Pharmaceutical Journal. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The PJ Pod and Pharmaceutical Journal eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Bruton tyrosine kinase (BTK) inhibitors are used to treat cancers caused by defective B cells, such as chronic lymphocytic leukaemia, B-cell lymphomas and Waldenström macroglobulinemia (WM). While B-cell malignancies are relatively rare cancers, their incidence is increasing. There are significant side effects and drug interactions associated with these therapies, and as the clinical use of BTK inhibitors increases, so does the need for pharmacists and pharmacy teams to be aware of them. In this episode of The PJ Pod, Caitlin Killen, assistant clinical editor, speaks to a patient who has received these therapies, as well as with two experts to find out more about the different BTK inhibitor classes, their mechanisms of action and considerations for their use in practice, with a focus on WM.

… continue reading

46 episoder

#Science #PJ Pod #Pharmaceutical Journal

Artwork

BTK inhibitors: what pharmacists need to know

published 12M ago

Del

MP3•Episode hjem

Indhold leveret af The PJ Pod and Pharmaceutical Journal. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The PJ Pod and Pharmaceutical Journal eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Bruton tyrosine kinase (BTK) inhibitors are used to treat cancers caused by defective B cells, such as chronic lymphocytic leukaemia, B-cell lymphomas and Waldenström macroglobulinemia (WM). While B-cell malignancies are relatively rare cancers, their incidence is increasing. There are significant side effects and drug interactions associated with these therapies, and as the clinical use of BTK inhibitors increases, so does the need for pharmacists and pharmacy teams to be aware of them. In this episode of The PJ Pod, Caitlin Killen, assistant clinical editor, speaks to a patient who has received these therapies, as well as with two experts to find out more about the different BTK inhibitor classes, their mechanisms of action and considerations for their use in practice, with a focus on WM.

… continue reading

46 episoder

#Science #PJ Pod #Pharmaceutical Journal

Alle episoder

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner